Coherus (CHRS) Q1 2026 earnings review
LOQTORZI Stalls as Coherus Pins Hopes on Mid-2026 Pipeline Readouts
Coherus has completed its transformation into a pure-play oncology innovator, but its sole commercial engine hit a speed bump. LOQTORZI revenue declined 5% sequentially to $11.8 million, breaking a streak of steady quarterly growth. Management attributed the deceleration to severe weather events and seasonality, but the dip raises questions about the timeline to the stated $150-$200 million peak sales target. On the positive side, aggressive cost-cutting slashed the quarterly net loss to $36.9 million, leaving the company with $167 million in cash—a sufficient runway to reach critical clinical data readouts for its CCR8 and IL-27 programs in mid-to-late 2026.
🐂 Bull Case
Total operating expenses fell significantly, with SG&A down to $23.1M and R&D dropping to $21.5M. This disciplined cost control ensures the $167M cash balance provides runway well past binary clinical readouts.
Enrollment is fully complete for the randomized Phase 2 trial of casdozokitug in 1L HCC. The first data readout is tracking for mid-2026, setting up a major potential catalyst for the stock.
🐻 Bear Case
LOQTORZI sequential revenue reversed into a 5% decline. If Coherus cannot successfully penetrate the community oncology setting against entrenched off-label PD-1 habits, the drug will fail to adequately fund pipeline development.
With the biosimilar safety net gone, Coherus's valuation is entirely dependent on the clinical success of tagmokitug and casdozokitug. Any failure in upcoming 2026 data readouts could be catastrophic.
⚖️ Verdict: ⚪
Neutral. Management successfully right-sized the balance sheet and eliminated the debt overhang (down 90%). However, the stalling of LOQTORZI revenue is concerning. The stock is a holding pattern until the mid-2026 clinical data readouts dictate the next major move.
Key Themes
LOQTORZI Revenue Reverses Sequentially
Following steady QoQ growth throughout 2025 ($7.3M -> $10.0M -> $11.2M -> $12.4M), LOQTORZI revenue decelerated and reversed, falling 5% QoQ to $11.8M. Management cited 'severe weather events' and seasonality, pointing to 'the highest volume of new patient starts to date' as a counter-narrative. However, the hard revenue numbers contradict the bullish commentary and highlight the inherent difficulty of scaling a rare disease drug in the fragmented community oncology setting.
Operating Expense Rightsizing Stabilizes Burn
The exit from the biosimilar business is finally showing its full impact on the bottom line. SG&A expenses decelerated to $23.1 million (down from $26.0 million in 25Q1) due to lower headcount. R&D expenses fell to $21.5 million from $24.4 million, reflecting reduced infrastructure costs that offset ongoing development for casdozokitug. This stable trajectory of cost containment is Coherus's most reliable internal growth driver right now.
Tagmokitug (CCR8) Scientific Differentiation
Management continues to beat the drum on tagmokitug (formerly CHS-114) as a best-in-class asset. The thesis is built on extreme selectivity: preclinical and clinical biomarker research shows it preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with zero off-target binding. This precise cytolytic targeting allows a pronounced increase in intratumoral CD8 T cells without the toxicities seen in less selective competitors.
Casdozokitug Mid-2026 Milestone De-Risked by Enrollment
The company announced that patient accrual is complete for the 1L HCC Phase 2 randomized clinical trial of casdozokitug in combination with LOQTORZI and bevacizumab. This removes a significant operational risk and locks in the mid-2026 timeline for initial data—the most critical catalyst for the company this year.
Macro Impact: Severe Weather Hit Sales
For the first time in recent quarters, management explicitly cited a macro factor—severe weather events in Q1—as a primary reason for the 5% sequential drop in LOQTORZI revenue. While plausible, it masks true underlying demand trends and requires close monitoring in Q2 to ensure this wasn't an excuse for competitive losses against off-label Keytruda.
Single Commercial Asset Concentration
With UDENYCA and other biosimilars gone, Coherus relies 100% on LOQTORZI to generate commercial revenue. The current $11.8M quarterly run rate is far from sufficient to offset the $36.9 million operating loss, maintaining heavy pressure on the balance sheet until global partnerships or pipeline validations occur.
Other KPIs
Down slightly from $172.1 million at the end of 2025, but bolstered by a $53.6 million net public equity offering during the quarter. Notably, this balance includes $61.6 million in TSA-related collections that will be directly applied to corresponding TSA payables, meaning true unencumbered cash is closer to ~$105 million.
Stable and successfully de-risked. Management highlighted that secured and convertible debt has been reduced by 90% from a peak of $480 million during the 2024-2025 timeframe. This fundamental restructuring is a major win for balance sheet survival.
Guidance
Enrollment is complete. The company is on track to deliver initial data around mid-year. Positive data here could unlock significant ex-U.S. partnering opportunities and non-dilutive capital.
Phase 1b dose optimization studies are underway. Expected to read out simultaneously with Casdozokitug, setting up a massive binary event window for the stock in Q2/Q3.
Further data expected in the second half of the year across esophageal squamous cell carcinoma and heavily pretreated colorectal cancer. This establishes a continuous catalyst chain throughout 2026.
Key Questions
Weather vs. Execution
You attributed the sequential decline in LOQTORZI to severe weather and seasonality, yet highlighted the highest volume of new patient starts to date. Can you quantify the specific revenue impact of the weather versus inventory drawdowns, and how did duration of therapy trend exactly?
TSA Financial Dynamics
Of the $167 million in cash, you noted $61.6 million is tied up in TSA-related collections earmarked for payables. Can you outline the exact timeline for these TSA obligations to burn off, and what is your true operational cash runway excluding these pass-through funds?
Ex-U.S. Partnering Leverage
You've stated that mid-2026 clinical data will drive ex-U.S. licensing deals. Are you already engaged in term-sheet level discussions based on the ongoing blinded data, or are partners firmly waiting for the final mid-year readout before acting?